Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.

ABSTRACT:

Purpose of review

This review offers a critical narrative evaluation of emerging evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective effects in people with type 2 diabetes.

Recent findings

The SGLT2 inhibitor class of glucose-lowering agents has recently shown beneficial effects to reduce the onset and progression of renal complications in people with and without diabetes. Randomised clinical trials and 'real world' observational studies, mostly involving type 2 diabetes patients, have noted that use of an SGLT2 inhibitor can slow the decline in glomerular filtration rate (GFR), reduce the onset of microalbuminuria and slow or reverse the progression of proteinuria. The nephroprotective effects of SGLT2 inhibitors are class effects observe

SUBMITTER: Bailey CJ 

PROVIDER: S-EPMC8888485 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature